Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

NZ sharemarket claws back to end the week up 0.5%
Markets Market close

NZ sharemarket claws back to end the week up 0.5%

Index rumours drive prices on two shares. 

Graham Skellern 13 Dec 2024
Staff leave Meridian after retail 'reset'
Markets

Staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

John Anthony 13 Dec 2024
NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Greg Hurrell 13 Dec 2024
Cannasouth delisting keeps Petterson in charge
Markets

Cannasouth delisting keeps Petterson in charge

Cannasouth major shareholders pushed to end voluntary administration they had called in.

Garth Bray 13 Dec 2024